Two decades of leukemia oncoprotein epistasis: The MLL1 paradigm for epigenetic deregulation in leukemia

Experimental Hematology

Volumn 42, Issue 12, 2014, Pages 995-1012

  Li, Bin E ^a   Ernst, Patricia ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; HISTONE LYSINE METHYLTRANSFERASE; MLL PROTEIN, HUMAN; MLL PROTEIN, MOUSE; MULTIPROTEIN COMPLEX; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ALLELE; CHROMOSOME 11; CHROMOSOME TRANSLOCATION; DRUG RESISTANCE; EPIGENETICS; EPISTASIS; GENE DISRUPTION; GENE REARRANGEMENT; GENOME ANALYSIS; GENOMICS; HUMAN; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; ONCOGENE; REVIEW; XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; CHROMATIN ASSEMBLY AND DISASSEMBLY; EXPERIMENTAL LEUKEMIA; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC EPIGENESIS; GENETICS; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALIA;

ALLELES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCK-IN TECHNIQUES; HETEROGRAFTS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; MICE; MULTIPROTEIN COMPLEXES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84919478152     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.09.006     Document Type: Review

References (179)

1. Nowell P.C., Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497.
2. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
3. Rowley J.D. Ph1-positive leukaemia, including chronic myelogenous leukaemia. Clin Haematol 1980, 9:55-86.
4. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
5. Tkachuk D.C., Kohler S., Cleary M.L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992, 71:691-700.
6. Gu Y., Nakamura T., Alder H., et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992, 71:701-708.
7. Djabali M., Selleri L., Parry P., Bower M., Young B.D., Evans G.A. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1992, 2:113-118.
8. Domer P.H., Fakharzadeh S.S., Chen C.S., et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci U S A 1993, 90:7884-7888.
9. Jansen M.W., Corral L., van der Velden V.H., et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007, 21:633-641.
10. Neff T., Armstrong S.A. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood 2013, 121:4847-4853.
11. Dobson C.L., Warren A.J., Pannell R., et al. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J 1999, 18:3564-3574.
12. Lavau C., Szilvassy S.J., Slany R., Cleary M.L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997, 16:4226-4237.
13. Corral J., Lavenir I., Impey H., et al. An MLL-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996, 85:853-861.
14. Slany R.K., Lavau C., Cleary M.L. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998, 18:122-129.
15. Dobson C.L., Warren A.J., Pannell R., Forster A., Rabbitts T.H. Tumorigenesis in mice with a fusion of the leukaemia oncogene MLL and the bacterial lacZ gene. EMBO J 2000, 19:843-851.
16. Muntean A.G., Hess J.L. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 2012, 7:283-301.
17. Chen W., Li Q., Hudson W.A., Kumar A., Kirchhof N., Kersey J.H. A murine MLL-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 2006, 108:669-677.
18. Metzler M., Forster A., Pannell R., et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 2006, 25:3093-3103.
19. Drynan L.F., Pannell R., Forster A., et al. MLL fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J 2005, 24:3136-3146.
20. So C.W., Karsunky H., Passegue E., Cozzio A., Weissman I.L., Cleary M.L. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 2003, 3:161-171.
21. Zeisig B.B., Garcia-Cuellar M.P., Winkler T.H., Slany R.K. The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene 2003, 22:1629-1637.
22. Krivtsov A.V., Feng Z., Lemieux M.E., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
23. Barabe F., Kennedy J.A., Hope K.J., Dick J.E. Modeling the initiation and progression of human acute leukemia in mice. Science 2007, 316:600-604.
24. Wei J., Wunderlich M., Fox C., et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008, 13:483-495.
25. Montes R., Ayllon V., Gutierrez-Aranda I., et al. Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood 2011, 117:4746-4758.
26. Kong C.T., Sham M.H., So C.W., Cheah K.S., Chen S.J., Chan L.C. The MLL-Een knockin fusion gene enhances proliferation of myeloid progenitors derived from mouse embryonic stem cells and causes myeloid leukaemia in chimeric mice. Leukemia 2006, 20:1829-1839.
27. Schichman S.A., Caligiuri M.A., Gu Y., et al. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci U S A 1994, 91:6236-6239.
28. Zorko N.A., Bernot K.M., Whitman S.P., et al. MLL partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 2012, 120:1130-1136.
29. Zhang Y., Yan X., Chen A., Sashida G., Xiao Z., Huang G. Modeling and targeting MLL-PTD/RUNX1 related MDS/AML in mouse. Blood Abstract 2013, 122.
30. Gaidzik V.I., Bullinger L., Schlenk R.F., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011, 29:1364-1372.
31. Dorrance A.M., Liu S., Yuan W., et al. MLL partial tandem duplication induces aberrant Hox expression invivo via specific epigenetic alterations. J Clin Invest 2006, 116:2707-2716.
32. Yokoyama A., Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008, 14:36-46.
33. Caslini C., Yang Z., El-Osta M., Milne T.A., Slany R.K., Hess J.L. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res 2007, 67:7275-7283.
34. Wang E.H., Ebrahimi S.A., Wu A.Y., Kashefi C., Passaro E., Sawicki M.P. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 1998, 58:4417-4420.
35. Yokoyama A., Somervaille T.C., Smith K.S., Rozenblatt-Rosen O., Meyerson M., Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123:207-218.
36. Hughes C.M., Rozenblatt-Rosen O., Milne T.A., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 2004, 13:587-597.
37. Eidahl J.O., Crowe B.L., North J.A., et al. Structural basis for high-affinity binding of LEDGF PWWP to mononucleosomes. Nucleic Acids Res 2013, 41:3924-3936.
38. Mereau H., De Rijck J., Cermakova K., et al. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Leukemia 2013, 27:1245-1253.
39. Murai M.J., Chruszcz M., Reddy G., Grembecka J., Cierpicki T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem 2011, 286:31742-31748.
40. Huang J., Gurung B., Wan B., et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 2012, 482:542-546.
41. Grembecka J., He S., Shi A., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012, 8:277-284.
42. Shi A., Murai M.J., He S., et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012, 120:4461-4469.
43. Li B.E., Gan T., Meyerson M., Rabbitts T.H., Ernst P. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood 2013, 122:2039-2046.
44. Wang Q.F., Wu G., Mi S., et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011, 117:6895-6905.
45. Ayton P.M., Chen E.H., Cleary M.L. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol 2004, 24:10470-10478.
46. Xia Z.B., Anderson M., Diaz M.O., Zeleznik-Le N.J. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci U S A 2003, 100:8342-8347.
47. Bach C., Mueller D., Buhl S., Garcia-Cuellar M.P., Slany R.K. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene 2009, 28:815-823.
48. Risner L.E., Kuntimaddi A., Lokken A.A., et al. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J Biol Chem 2013, 288:29901-29910.
49. Cierpicki T., Risner L.E., Grembecka J., et al. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol 2010, 17:62-68.
50. Milne T.A., Kim J., Wang G.G., et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 2010, 38:853-863.
51. Muntean A.G., Tan J., Sitwala K., et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010, 17:609-621.
52. Rosonina E., Manley J.L. From transcription to mRNA: PAF provides a new path. Mol Cell 2005, 20:167-168.
53. Zhu B., Zheng Y., Pham A.D., et al. Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell 2005, 20:601-611.
54. Muntean A.G., Chen W., Jones M., Granowicz E.M., Maillard I., Hess J.L. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood 2013, 122:1914-1922.
55. Wang E., Kawaoka S., Yu M., et al. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc Natl Acad Sci U S A 2013, 110:3901-3906.
56. Arora M., Zhang J., Heine G.F., et al. Promoters active in interphase are bookmarked during mitosis by ubiquitination. Nucleic Acids Res 2012, 40:10187-10202.
57. Shiloh Y., Shema E., Moyal L., Oren M. RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response. FEBS Lett 2011, 585:2795-2802.
58. Schuettengruber B., Cavalli G. Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development 2009, 136:3531-3542.
59. Hess J.L., Bittner C.B., Zeisig D.T., et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 2006, 108:297-304.
60. Huang Y., Sitwala K., Bronstein J., et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012, 119:388-398.
61. Zuber J., Rappaport A.R., Luo W., et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 2011, 25:1628-1640.
62. Ernst P., Wang J., Huang M., Goodman R.H., Korsmeyer S.J. MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol 2001, 21:2249-2258.
63. De Guzman R.N., Goto N.K., Dyson H.J., Wright P.E. Structural basis for cooperative transcription factor binding to the CBP coactivator. J Mol Biol 2006, 355:1005-1013.
64. Jin S., Zhao H., Yi Y., Nakata Y., Kalota A., Gewirtz A.M. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 2010, 120:593-606.
65. Jiang X., Huang H., Li Z., et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 2012, 22:524-535.
66. Bousquet M., Zhuang G., Meng C., et al. miR-150 blocks MLL-AF9-associated leukemia through oncogene repression. Mol Cancer Res 2013, 11:912-922.
67. Cho E.C., Mitton B., Sakamoto K.M. CREB and leukemogenesis. Crit Rev Oncog 2011, 16:37-46.
68. Wang Z., Iwasaki M., Ficara F., et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010, 17:597-608.
69. Rowley J.D., Reshmi S., Sobulo O., et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997, 90:535-541.
70. Lavau C., Du C., Thirman M., Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 2000, 19:4655-4664.
71. Wang J., Iwasaki H., Krivtsov A., et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 2005, 24:368-381.
72. Swiers G., de Bruijn M., Speck N.A. Hematopoietic stem cell emergence in the conceptus and the role of Runx1. Int J Dev Biol 2010, 54:1151-1163.
73. Mangan J.K., Speck N.A. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog 2011, 16:77-91.
74. Tang J.L., Hou H.A., Chen C.Y., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114:5352-5361.
75. Network TCGAR Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074.
76. Nishimoto N., Arai S., Ichikawa M., et al. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. Blood 2011, 118:2541-2550.
77. Goyama S., Schibler J., Cunningham L., et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest 2013, 123:3876-3888.
78. Bernt K.M., Zhu N., Sinha A.U., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
79. Guenther M.G., Lawton L.N., Rozovskaia T., et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008, 22:3403-3408.
80. Wilkinson A.C., Ballabio E., Geng H., et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep 2013, 3:116-127.
81. Yu M., Mazor T., Huang H., et al. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell 2012, 45:330-343.
82. Huang G., Zhao X., Wang L., et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 2011, 118:6544-6552.
83. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010, 10:457-469.
84. Yokoyama A., Lin M., Naresh A., Kitabayashi I., Cleary M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
85. Lin C., Smith E.R., Takahashi H., et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010, 37:429-437.
86. Adelman K., Lis J.T. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat Rev Genet 2012, 13:720-731.
87. Bitoun E., Oliver P.L., Davies K.E. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007, 16:92-106.
88. Okada Y., Feng Q., Lin Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
89. Nguyen A.T., Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011, 25:1345-1358.
90. He N., Chan C.K., Sobhian B., et al. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci US A 2011, 108:E636-645.
91. Daigle S.R., Olhava E.J., Therkelsen C.A., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
92. Deshpande A.J., Chen L., Fazio M., et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 2013, 121:2533-2541.
93. Kühn MWM, Hadler M, Daigle SR, etal. Myeloid leukemia cells with MLL partial tandem duplication are sensitive to pharmacological inhibition of the H3K79 methyltransferase DOT1L ASH Abstract.2013.
94. Wolf S.S. The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans. Cell Mol Life Sci 2009, 66:2109-2121.
95. Cheung N., Chan L.C., Thompson A., Cleary M.L., So C.W. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007, 9:1208-1215.
96. Argiropoulos B., Humphries R.K. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007, 26:6766-6776.
97. Ayton P.M., Cleary M.L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003, 17:2298-2307.
98. Kumar A.R., Hudson W.A., Chen W., Nishiuchi R., Yao Q., Kersey J.H. Hoxa9 influences the phenotype but not the incidence of MLL-AF9 fusion gene leukemia. Blood 2004, 103:1823-1828.
99. So C.W., Karsunky H., Wong P., Weissman I.L., Cleary M.L. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 2004, 103:3192-3199.
100. Bijl J., Thompson A., Ramirez-Solis R., et al. Analysis of HSC activity and compensatory Hox gene expression profile in Hoxb cluster mutant fetal liver cells. Blood 2006, 108:116-122.
101. Longobardi E., Penkov D., Mateos D., De Florian G., Torres M., Blasi F. Biochemistry of the tale transcription factors PREP, MEIS, and PBX in vertebrates. Dev Dyn 2014, 243:59-75.
102. Kumar A.R., Li Q., Hudson W.A., et al. A role for MEIS1 in MLL-fusion gene leukemia. Blood 2009, 113:1756-1758.
103. Wong P., Iwasaki M., Somervaille T.C., So C.W., Cleary M.L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 2007, 21:2762-2774.
104. Li Z., Zhang Z., Li Y., et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood 2013, 121:1422-1431.
105. Artinger E.L., Mishra B.P., Zaffuto K.M., et al. An MLL-dependent network sustains hematopoiesis. Proc Natl Acad Sci U S A 2013, 10:12000-12005.
106. Tadjuidje E., Hegde R.S. The Eyes Absent proteins in development and disease. Cell Mol Life Sci 2013, 70:1897-1913.
107. Lee J.W., Kim H.S., Hwang J., et al. Regulation of HOXA9 activity by predominant expression of DACH1 against C/EBPalpha and GATA-1 in myeloid leukemia with MLL-AF9. Biochem Biophys Res Commun 2012, 426:299-305.
108. Popovic R., Riesbeck L.E., Velu C.S., et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009, 113:3314-3322.
109. Schotte D., Lange-Turenhout E.A., Stumpel D.J., et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 2010, 95:1675-1682.
110. Beachy S.H., Onozawa M., Silverman D., Chung Y.J., Rivera M.M., Aplan P.D. Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia. Exp Hematol 2013, 41:518-529. e515.
111. Li Z., Huang H., Chen P., et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 2012, 3:688.
112. Velu C.S., Chaubey A., Phelan J.D., et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest 2014, 124:222-236.
113. Davidson A.J., Ernst P., Wang Y., et al. cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature 2003, 425:300-306.
114. Wang Y., Yabuuchi A., McKinney-Freeman S., et al. Cdx gene deficiency compromises embryonic hematopoiesis in the mouse. Proc Natl Acad Sci U S A 2008, 105:7756-7761.
115. Scholl C., Bansal D., Dohner K., et al. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest 2007, 117:1037-1048.
116. Koo S., Huntly B.J., Wang Y., et al. Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica 2010, 95:1642-1650.
117. Metais J.Y., Dunbar C.E. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther 2008, 16:439-449.
118. Groschel S., Lugthart S., Schlenk R.F., et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010, 28:2101-2107.
119. Bindels E.M., Havermans M., Lugthart S., et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 2012, 119:5838-5849.
120. Zhang Y., Stehling-Sun S., Lezon-Geyda K., et al. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood 2011, 118:3853-3861.
121. Arai S., Yoshimi A., Shimabe M., et al. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 2011, 117:6304-6314.
122. Goyama S., Yamamoto G., Shimabe M., et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008, 3:207-220.
123. Zhang Y., Owens K., Hatem L., et al. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia. Blood 2013, 122:2888-2892.
124. Krivtsov A.V., Figueroa M.E., Sinha A.U., et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013, 27:852-860.
125. Schwieger M., Schuler A., Forster M., et al. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood 2009, 114:2476-2488.
126. Krivtsov A.V., Twomey D., Feng Z., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
127. Miller P.G., Al-Shahrour F., Hartwell K.A., et al. InVivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 2013, 24:45-58.
128. Schreiner S., Birke M., Garcia-Cuellar M.P., Zilles O., Greil J., Slany R.K. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res 2001, 61:6480-6486.
129. Blobel G.A., Kadauke S., Wang E., et al. A reconfigured pattern of MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit. Mol Cell 2009, 36:970-983.
130. Dawson M.A., Prinjha R.K., Dittmann A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
131. Zuber J., Shi J., Wang E., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
132. Barbieri I., Cannizzaro E., Dawson M.A. Bromodomains as therapeutic targets in cancer. Brief Funct Genomics 2013, 12:219-230.
133. Armstrong S.A., Golub T.R., Korsmeyer S.J. MLL-rearranged leukemias: insights from gene expression profiling. Semin Hematol 2003, 40:268-273.
134. Stubbs M.C., Kim Y.M., Krivtsov A.V., et al. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 2008, 22:66-77.
135. Gwin K., Frank E., Bossou A., Medina K.L. Hoxa9 regulates Flt3 in lymphohematopoietic progenitors. J Immunol 2010, 185:6572-6583.
136. Albouhair S., Morgado E., Lavau C. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes. PLoS One 2013, 8:e72261.
137. Kamezaki K., Luchsinger L., Snoeck H.W. Differential requirement for wild-type Flt3 in leukemia-initiation among mouse models of human leukemia. Exp Hematol 2014, 42:192-203.e1.
138. Driessen E.M., van Roon E.H., Spijkers-Hagelstein J.A., et al. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica 2013, 98:937-944.
139. Kim W.I., Matise I., Diers M.D., Largaespada D.A. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood 2009, 113:1086-1096.
140. Ono R., Kumagai H., Nakajima H., et al. Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia 2009, 23:2197-2209.
141. Tamai H., Miyake K., Takatori M., et al. Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia 2011, 25:888-891.
142. Ng M.H., Ng R.K., Kong C.T., Jin D.Y., Chan L.C. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins. Exp Hematol 2010, 38:481-488.
143. Nakanishi H., Nakamura T., Canaani E., Croce C.M. ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci U S A 2007, 104:14442-14447.
144. Manara E., Baron E., Tregnago C., et al. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood 2014, 124:263-272.
145. Wang Y., Krivtsov A.V., Sinha A.U., et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
146. Yeung J., Esposito M.T., Gandillet A., et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010, 18:606-618.
147. Staal F.J., Luis T.C. Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions. J Cell Biochem 2010, 109:844-849.
148. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
149. de la Roche M., Rutherford T.J., Gupta D., et al. An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-catenin is required for its inhibition by carnosic acid. Nat Commun 2012, 3:680.
150. Wang X., Zhu K., Li S., et al. MLL1, a H3K4 methyltransferase, regulates the TNFalpha-stimulated activation of genes downstream of NF-kappaB. J Cell Sci 2012, 125:4058-4066.
151. Austenaa L., Barozzi I., Chronowska A., et al. The histone methyltransferase Wbp7 controls macrophage function through GPI glycolipid anchor synthesis. Immunity 2012, 36:572-585.
152. Kuo H.P., Wang Z., Lee D.F., et al. Epigenetic roles of MLL oncoproteins are dependent on NF-kappaB. Cancer Cell 2013, 24:423-437.
153. Ohlsson E., Hasemann M.S., Willer A., et al. Initiation of MLL-rearranged AML is dependent on C/EBPalpha. J Exp Med 2014, 211:5-13.
154. Zhou J., Wu J., Li B., et al. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. Leukemia 2014, 28:1436-1448.
155. Mills A.A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer 2010, 10:669-682.
156. Schuettengruber B., Martinez A.M., Iovino N., Cavalli G. Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 2011, 12:799-814.
157. Tanaka S., Miyagi S., Sashida G., et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012, 120:1107-1117.
158. Neff T., Sinha A.U., Kluk M.J., et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A 2012, 109:5028-5033.
159. Xie H., Xu J., Hsu J.H., et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 2014, 14:68-80.
160. Shi J., Wang E., Zuber J., et al. The Polycomb complex PRC2supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene 2013, 32:930-938.
161. Kim W., Bird G.H., Neff T., et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 2013, 9:643-650.
162. Yuan J., Takeuchi M., Negishi M., Oguro H., Ichikawa H., Iwama A. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 2011, 25:1335-1343.
163. Smith L.L., Yeung J., Zeisig B.B., et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011, 8:649-662.
164. Tan J., Jones M., Koseki H., et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 2011, 20:563-575.
165. Maethner E., Garcia-Cuellar M.P., Breitinger C., et al. MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep 2013, 3:1553-1566.
166. Nakamura T., Mori T., Tada S., et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002, 10:1119-1128.
167. Harris W.J., Huang X., Lynch J.T., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
168. Kerenyi M.A., Shao Z., Hsu Y.J., et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife 2013, 2:e00633.
169. Thiel A.T., Blessington P., Zou T., et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type MLL allele. Cancer Cell 2010, 17:148-159.
170. Mishra B.P., Zaffuto K.M., Artinger E.L., et al. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep 2014, 7:1239-1247.
171. Osaki H., Walf-Vorderwulbecke V., Mangolini M., et al. The AAA ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis. Leukemia 2013, 27:1461-1468.
172. Shi J., Whyte W.A., Zepeda-Mendoza C.J., et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev 2013, 27:2648-2662.
173. Stumpel D.J., Schneider P., van Roon E.H., Pieters R., Stam R.W. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer 2013, 49:175-184.
174. Schafer E., Irizarry R., Negi S., et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 2010, 115:4798-4809.
175. Bernot K.M., Nemer J.S., Santhanam R., et al. Eradicating acute myeloid leukemia in a MLLPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease. Blood 2013, 122:3778-3783.
176. Trowbridge J.J., Sinha A.U., Zhu N., Li M., Armstrong S.A., Orkin S.H. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012, 26:344-349.
177. Broske A.M., Vockentanz L., Kharazi S., et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 2009, 41:1207-1215.
178. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
179. Huang H., Jiang X., Li Z., et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A 2013, 110:11994-11999.